AUPH News and Press, Aurinia Pharmaceuticals Inc From 12/21/20

Aurinia Pharmaceuticals has one of the most important milestones in its history in a few weeks. Next January 22, 2021 is the PDUFA where the FDA will decide the approval of the candidate drug Voclosporin. Voclosporin approval by the FDA is almost assured thanks to the very good ph...

Aurinia Pharmaceuticals (AUPH) has entered into a collaboration and license agreement with Otsuka Pharmaceutical for the development and commercialization of oral voclosporin for the treatment of Lupus Nephritis ((LN)) in the European Union ((EU)), Japan, U.K., Russia, Switzerland, Norway, Be...

- Aurinia to receive $50 million U.S. upfront payment in addition to up to $50 million U.S. in regulatory and reimbursement milestone payments - - Agreement includes royalties of up to 20 percent on net sales payable to Aurinia - Aurinia Pharmaceuticals Inc. (NASDAQ:...

- State-of-the-Art Monoplant Will Provide Cost and Production Efficiency and Secure Active Pharmaceutical Ingredient (API) Supply for Future Commercial Demand - Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (“Aurinia”) and Lonza Ltd. (SIX: LONN...

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the “Company”) today announced its participation in the Piper Sandler 32 nd Annual Virtual Healthcare Conference. Presentations will be available for registered attendees via the Piper Sandler conference site thro...

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company, today announced that the Company’s Compensation Committee granted the newly appointed Executive Vice President, General ...

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the “Company”) today announced that members of the senior management team will participate in a fireside chat during the 2020 Jefferies Virtual London Healthcare Conference on November 19, 2020 at 11:25 a.m. ET. I...

Aurinia Pharma (AUPH): Q3 GAAP EPS of -$0.28 misses by $0.05.Revenue of $0.03M (-87.0% Y/Y) misses by $0.01M.Cash, cash equivalents and investments of $421M.Press Release For further details see: Aurinia Pharma EPS misses by $0.05, misses on revenue

- U.S. Food & Drug Administration grants Priority Review for voclosporin and sets PDUFA date of January 22, 2021 - - Cash, cash equivalents and investments totaled approximately $421 million at September 30, 2020 - - Conference call and webcast to be hosted today a...

- Integrated analysis confirms addition of voclosporin to standard-of-care resulted in faster Renal Response compared to standard-of-care alone in lupus nephritis - - DDI study demonstrates no clinically meaningful interaction between voclosporin and MMF, supporting differenti...